Table Info

Table 3.

Data on serum lipids, lipoproteins, and HbA_1c levels in different groups of rs738409 SNP of the PNPLA3 gene after subgroup analysis according to obesity

Parameter	Obese (n = 78)					Non-obese (n = 87)
	PNPLA3 genotype
	CC (n = 38)	CG (n = 34)	GG (n = 6)	P value^*	P value^†	CC (n = 44)	CG (n = 37)	GG (n = 6)	P value^*	P value^†
TC (mg/dL)	226 ± 44	238 ± 41	233 ± 24	0.470	0.230	271 ± 54	240 ± 37	267 ± 39	0.014	0.009
TGs (mg/dL)	266 ± 186	249 ± 127	371 ± 291	0.288	0.772	252 ± 157	227 ± 119	275 ± 144	0.634	0.953
LDL-C (mg/dL)	142 ± 42	148 ± 44	139 ± 32	0.797	0.625	181 ± 56	153 ± 41	178 ± 42	0.046	0.027
HDL-C (mg/dL)	40.3 ± 8.7	39.7 ± 10.5	34.6 ± 6.8	0.400	0.541	41.2 ± 10	42.3 ± 11	44 ± 7.3	0.778	0.541
HbA_1c (%)	6.5 ± 1.13	6.1 ± 1.21	5.4 ± 0.23	0.062	0.088	5.9 ± 1.12	5.7 ± 0.86	5.4 ± 0.30	0.934	0.334

Data are presented as mean ± SD. * Additive genetic model (CC vs. CG vs. GG); † Dominant model (CC vs. GG + CG)

Declarations

Author contributions

DI: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Writing—review & editing. ESM: Data curation, Formal analysis, Visualization, Writing—original draft, Writing—review & editing. SAP: Data curation, Formal analysis, Validation, Visualization, Writing—original draft, Writing—review & editing. CN: Data curation, Investigation, Writing—review & editing. DA: Data curation, Writing—review & editing. GG: Data curation, Writing—review & editing. AG: Conceptualization, Supervision, Formal Analysis, Investigation, Validation, Methodology, Writing—review & editing.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the Declaration of Helsinki 1964 and its later amendments or comparable ethical standards. The study was approved by the Bioethics Committee of the Medical School of Aristotle University of Thessaloniki.

Consent to participate

Informed consent was obtained from all the participants included in the study.

Consent to publication

Not applicable.

Availability of data and materials

The data associated with the paper are not publicly available but are available from the corresponding author on reasonable request.

Funding

Not applicable.

Copyright

References

Wilson PA, Gardner SD, Lambie NM, Commans SA, Crowther DJ. Characterization of the human patatin-like phospholipase family^s⃞. J Lipid Res. 2006;47:1940–9. [DOI] [PubMed]

Huang Y, Cohen JC, Hobbs HH. Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease^*. J Biol Chem. 2011;286:37085–93. [DOI] [PubMed] [PMC]

Jenkins CM, Mancuso DJ, Yan W, Sims HF, Gibson B, Gross RW. Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A₂ family members possessing triacylglycerol lipase and acylglycerol transacylase activities^*. J Biol Chem. 2004;279:48968–75. [DOI] [PubMed]

Kumari M, Schoiswohl G, Chitraju C, Paar M, Cornaciu I, Rangrez AY, et al. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab. 2012;15:691–702. [DOI] [PubMed] [PMC]

Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461–5. [DOI] [PubMed] [PMC]

Dai G, Liu P, Li X, Zhou X, He S. Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease (NAFLD) susceptibility and severity: a meta-analysis. Medicine. 2019;98:e14324. [DOI] [PubMed] [PMC]

Polyzos SA, Mantzoros CS. An update on the validity of irisin assays and the link between irisin and hepatic metabolism. Metabolism. 2015;64:937–42. [DOI] [PubMed]

He S, McPhaul C, Li JZ, Garuti R, Kinch L, Grishin NV, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis*. J Biol Chem. 2010;285:6706–15. [DOI] [PubMed] [PMC]

BasuRay S, Smagris E, Cohen JC, Hobbs HH. The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation. Hepatology. 2017;66:1111–24. [DOI] [PubMed] [PMC]

10.

Stender S, Kozlitina J, Nordestgaard BG, Tybjærg-Hansen A, Hobbs HH, Cohen JC. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nat Genet. 2017;49:842–7. [DOI] [PubMed] [PMC]

11.

Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502. [DOI] [PubMed]

12.

Mouskeftara T, Goulas A, Ioannidou D, Ntenti C, Agapakis D, Assimopoulou A, et al. A study of blood fatty acids profile in hyperlipidemic and normolipidemic subjects in association with common PNPLA3 and ABCB1 polymorphisms. Metabolites. 2021;11:90. [DOI] [PubMed] [PMC]

13.

Zhang L, You W, Zhang H, Peng R, Zhu Q, Yao A, et al. PNPLA3 polymorphisms (rs738409) and non-alcoholic fatty liver disease risk and related phenotypes: a meta-analysis. J Gastroenterol Hepatol. 2015;30:821–9. [DOI] [PubMed]

14.

Qadri S, Lallukka-Brück S, Luukkonen PK, Zhou Y, Gastaldelli A, Orho-Melander M, et al. The PNPLA3-I148M variant increases polyunsaturated triglycerides in human adipose tissue. Liver Int. 2020;40:2128–38. [DOI] [PubMed]

15.

Luukkonen PK, Qadri S, Lehtimäki TE, Juuti A, Sammalkorpi H, Penttilä AK, et al. The PNPLA3-I148M variant confers an antiatherogenic lipid profile in insulin-resistant patients. J Clin Endocrinol Metab. 2021;106:e300–15. [DOI] [PubMed]

16.

Park JH, Cho B, Kwon H, Prilutsky D, Yun JM, Choi HC, et al. I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease. Liver Int. 2015;35:2537–46. [DOI] [PubMed]

17.

Wang CW, Lin HY, Shin SJ, Yu ML, Lin ZY, Dai CY, et al. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population. Liver Int. 2011;31:1326–31. [DOI] [PubMed]

18.

Mantovani A, Taliento A, Zusi C, Baselli G, Prati D, Granata S, et al. PNPLA3 I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: clinical and experimental findings. Liver Int. 2020;40:1130–41. [DOI] [PubMed]

19.

Karamfilova V, Gateva A, Assyov Y, Alexiev A, Savov A, Yaneva N, et al. PNPLA3 I148M polymorphism in patients with nonalcoholic fatty liver disease, obesity and prediabetes. J Gastrointestin Liver Dis. 2019;28:433–8. [DOI] [PubMed]

20.

Luo Z, Liu Y, Li H, Zhou Y, Peng Y, Lin X, et al. Associations of PNPLA3 rs738409 polymorphism with plasma lipid levels: a systematic review and meta-analysis. Horm Metab Res. 2022;54:686–95. [DOI] [PubMed]